An engineered virus reveals potential as an immune remedy in glioblastoma

Therapies for aggressive, recurrent glioblastomas are sorely wanted however continuously fail in trials. A primary-in-human trial of CAN-3110, an engineered herpes simplex virus 1 (HSV1), reveals that it’s secure and appears to increase survival and stimulate immune responses — notably in individuals with antibodies to HSV1.